

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

SECTION 1. IDENTIFICATION

Product name : Letermovir Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Liver, spleen, Blood)

Short-term (acute) aquatic hazard : Category 3

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.
H402 Harmful to aquatic life.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

P260 Do not breathe dust.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 50
Letermovir	917389-32-3	>= 30 -< 50
Magnesium stearate	557-04-0	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. Suspected of damaging the unborn child.

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Nitrogen oxides (NO_x)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	CMP	10 mg/m ³	AR OEL
		TWA	10 mg/m ³	ACGIH
Letermovir	917389-32-3	TWA	0.4 mg/m ³ (OEB 2)	Internal
Magnesium stearate	557-04-0	CMP	10 mg/m ³	AR OEL
Further information: A4 - Not classifiable as a human carcinogen				
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA	3 mg/m ³	ACGIH

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

		(Respirable particulate matter)		
--	--	---------------------------------	--	--

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition	:	No hazardous decomposition products are known.

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Letermovir:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
LD50 (Mouse): > 2.000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Magnesium stearate:

Species : Rabbit

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Result: negative

Letermovir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Letermovir:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 240 mg/kg body weight
Result: No effects on fertility.

Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 180 mg/kg body weight
Result: No effects on fertility.
Remarks: The significance of these findings for humans is not certain.

Test Type: Fertility/early embryonic development
Species: Monkey, male
Application Route: Oral
Fertility: NOAEL: 240 mg/kg body weight
Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Developmental Toxicity: LOAEL: 250 mg/kg body weight
Result: Embryo-fetal toxicity.
Remarks: Maternal toxicity observed.

Test Type: Embryo-fetal development
Species: Rabbit
Developmental Toxicity: LOAEL: 225 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed., Abortion
Remarks: Maternal toxicity observed.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

Components:**Letermovir:**

Routes of exposure	: Ingestion
Target Organs	: Liver, spleen, Blood
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species	: Rat
NOAEL	: ≥ 9.000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Letermovir:

Species	: Mouse
NOAEL	: 40 mg/kg
LOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Liver, spleen

Species	: Rat
NOAEL	: 150 mg/kg
Application Route	: Oral
Exposure time	: 26 Weeks
Remarks	: No significant adverse effects were reported

Species	: Monkey
NOAEL	: 100 mg/kg
LOAEL	: 200 - 250 mg/kg
Application Route	: Oral
Exposure time	: 39 Weeks
Target Organs	: Kidney

Species	: Rat
NOAEL	: 60 mg/kg
LOAEL	: 180 mg/kg
Exposure time	: 13 Weeks

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Target Organs	:	Testis, Blood, Liver, spleen, Immune system
Species	:	Monkey
NOAEL	:	30 mg/kg
LOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	4 Weeks
Target Organs	:	Blood

Magnesium stearate:

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Letermovir:**

Ingestion	:	Symptoms: Diarrhea, Nausea, Vomiting, Headache, Dizziness, Fatigue, Back pain, Edema, Rash, muscle pain
-----------	---	---------------------------------------------------------------------------------------------------------

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	------------------------------------------------------------------------------------------------------------------------------

Letermovir:

Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
------------------	---	-------------------------------------------------------------------------------------------------------------

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamysis): 16 mg/l Exposure time: 96 h
-----------------------------------------------------	---	-----------------------------------------------------

	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
--	---	---------------------------------------------------------------------------------------------------------

Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 8,8 mg/l Exposure time: 72 h
----------------------------------	---	-----------------------------------------------------------------------------------------

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 8,8 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1,2 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 972 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 29,6 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Letermovir:Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 6,7 d**Magnesium stearate:**Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials**Bioaccumulative potential****Components:****Letermovir:**

Partition coefficient: n-octanol/water : log Pow: 2,29

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil**Components:****Letermovir:**

Distribution among environmental compartments : log Koc: 3,46

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 14.04.2025
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AR OEL : Argentina. Occupational Exposure Limits

Letermovir Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
8.2	14.04.2025	59329-00026	Date of first issue: 16.02.2015

ACGIH / TWA : 8-hour, time-weighted average
AR OEL / CMP : TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8